Q9995 — Injection, emicizumab-kxwh, 0.5 mg
Q9995 is a HCPCS Level II code for injection, emicizumab-kxwh, 0.5 mg. It belongs to the Temporary Codes section. It was terminated on December 31, 2018 and is not valid on new claims.
This code has been terminated
CMS terminated Q9995 on December 31, 2018. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for Q9995
- Long descriptor
- Injection, emicizumab-kxwh, 0.5 mg
- Short descriptor
- Inj., emicizumab-kxwh 0.5 mg
- Added
- July 1, 2018
- Terminated
- December 31, 2018
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to Q9995
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If Q9995 is not quite right, the correct code is very often within a few positions of it.
- Q9986Injection, hydroxyprogesterone caproate, (makena), 10 mgterminated
- Q9987Pathogen(s) test for plateletsterminated
- Q9988Platelets, pheresis, pathogen-reduced, each unitterminated
- Q9989Ustekinumab, for intravenous injection, 1 mgterminated
- Q9991Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg
- Q9992Injection, buprenorphine extended-release (sublocade), greater than 100 mg
- Q9993Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mgterminated
- Q9994In-line cartridge containing digestive enzyme(s) for enteral feeding, eachterminated
- Q9996Injection, ustekinumab-ttwe (pyzchiva), subcutaneous, 1 mg
- Q9997Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg
- Q9998Injection, ustekinumab-aekn (selarsdi), biosimilar, 1 mg
- Q9999Injection, ustekinumab-aauz (otulfi), biosimilar, 1 mg
- R0070Transportation of portable x-ray equipment and personnel to home or nursing home, per trip to facility or location, one patient seen
- R0075Transportation of portable x-ray equipment and personnel to home or nursing home, per trip to facility or location, more than one patient seen
- R0076Transportation of portable ekg to facility or location, per patient
- S0012Butorphanol tartrate, nasal spray, 25 mg
Questions about Q9995
What is HCPCS code Q9995?
Q9995 is a HCPCS Level II code for injection, emicizumab-kxwh, 0.5 mg. It sits in the Temporary Codes section.
Does Medicare cover Q9995?
The CMS HCPCS file marks Q9995 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
Is Q9995 still valid?
No. Q9995 was terminated on December 31, 2018 and should not be used on new claims.